Drug intelligence / Profile preview

granaticin b

Development stage: Phase 2
Lead developer: Lin BioScience
Modality: Small Molecules

Overview

Granaticin B is a small molecule antibiotic produced by certain strains of *Streptomyces violaceoruber*. It exhibits significant antibacterial activity against various Gram-positive bacteria through multiple proposed mechanisms including inhibition at early stages of RNA biosynthesis and oxidative effects on cellular components. Currently under investigation for use in acute leukemia due to its ability to inhibit cell division cycle proteins such as CDC7 kinase.

Other names: 8,11-ethanofuro(2,3-e)naphtho(2,3-c:6,7-c')dipyran-2,6,13(9h)-trione, 3,3a,5,8,11,13b-hexahydro-7,8,12-trihydroxy-5,9-dimethyl-15-(((2s,5s,s)-tetrahydro-5-hydroxy-methyl-pyran-yl)oxy)-,(3as,s,s,r,r,r)CKI-7 (Memorial Sloan-Kettering Cancer Center)granaticin B (Lin BioScience)

Targets

CDC7 (Cell division cycle 7-related protein kinase)

Beyond the preview

Go deeper on granaticin b.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on granaticin b.

Explore the full profile